WuXi AppTec

Unique, Integrated CRDMO Platform

WuXi AppTec

Statistics as of Q3 2025 (September 30, 2025)

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.

Our Vision

Every drug can be made and every disease can be treated.

Integrated Platform

Research **D**evelopment **M**anufacturing

Our History

2000

2025

from one single chemistry lab	▶	to a global enabling platform
from one customer	▶	to around 6,000 customers
from four co-founders	▶	to over 38,000 employees globally, including over 36,000 scientists and technicians

WuXi AppTec

A Global Footprint

China

Shanghai	R&D Headquarters / Drug Discovery and Preclinical /	Changshu	Small Molecule R&D and Manufacturing
Jinshan (Shanghai)	Small Molecule R&D and Manufacturing	Wuxi	Small Molecule Manufacturing
Changzhou	Small Molecule R&D and Manufacturing	Tianjin	Chemistry and Drug Discovery
Suzhou	Drug Safety Evaluation	Chengdu	Drug Discovery and Preclinical
Nanjing	DMPK and Bioanalytical	Wuhan	Chemistry and Drug Discovery
Nantong	Small Molecule R&D	Beijing	Government Affairs
Taixing	Small Molecule R&D and Manufacturing		

U.S.

Boston / Natick	MA	Compound Management / Logistics Center / Program Management
Cranbury	NJ	DMPK and Biology
San Diego	CA	Biology / Small Molecule Process Development and Manufacturing
Middletown	DE	Small Molecule Manufacturing

Germany

Munich	Drug Discovery /Biology

Switzerland

Couvet	Small Molecule Manufacturing

South Korea

Pan-Gyo	Program Management

Singapore

Singapore	Small Molecule R&D and Manufacturing

Japan

Kyoto	BD / Program Management

WuXi AppTec

Challenges Facing Today's Healthcare Industry

High R&D Costs

2Bn+

USD per drug on average[1]

Lengthy R&D Process

10+

years from discovery to market

Vast Research → Few Successes

Availability & Affordability

7k+

rare diseases mostly underserved

Low Success Rates

<10%

success rate from Phase I to filing[2]

Source: 1. Deloitte January, 2023, based on the top 20 pharma companies by R&D spend. 2. IQVIA, February, 2023

WuXi AppTec

Integrated End-to-End CRDMO Enabling Platform



WuXi AppTec

WuXi Chemistry

A comprehensive CRDMO platform that moves molecules from discovery to market.
Capacity and capabilities to support all phases of drug development at any scale for all synthetic molecular modalities.

- **430,000+** compounds (in the past 12 months); **3,430** preclinical, clinical and commercial drugs, including **87** Phase III clinical candidates and **80** commercial drugs (as of Q3 2025)
- Successful inspections by U.S. FDA, EU EMA, China NMPA, Japan PMDA, South Korea MFDS, and SwissMedic, and over **100** country approvals for branded drugs
- **700+** CMC submission packages written to support global IND and NDA filings from 2019 to 2024

WuXi Research Chemistry Services
Small Molecule Discovery

Medicinal Chemistry | Custom Synthesis | Library | Discovery Process Chemistry

- Delivered 430,000+ compounds (in the past 12 months)
- **Technology Platform**: Reaction Conditions Screening, Photoredox Chemistry, Flow Chemistry, Biocatalysis, Electrochemistry, Computer-Aided Drug Design
- **Specialty Chemistry**: Targeted Covalent Inhibitor, Targeted Protein Degrader, Fluorine Chemistry, Carbohydrate, Macrocycle, Organoboron, Stable Isotope Labeling

WuXi STA
Small Molecule
Development and Manufacturing

- Drug Substance | Drug Product | Analytical | Regulatory Dossier Preparation
- Approximately 4,000 m^3 total reactor volume for small molecule API and intermediate manufacturing
- **Drug Substance Enabling Technology Portfolio**: Crystallization & Particle Engineering, Biocatalysis, Chemo Catalysis, Flow Chemistry, Preparative HPLC & SFC & SMB, High Potency API
- **Drug Product Enabling Technology Portfolio**: Spray Dried Dispersion, Nano Suspension, Hot Melt Extrusion, Lipid Nanoparticle, High Potency Drug Product
- 5 drug product sites in North America, Europe, and Asia, supporting both oral solid and parenteral dosage forms

WuXi TIDES
Peptide and Oligonucleotide Discovery, Development, Manufacturing

Oligonucleotides | Peptides | Conjugates | Amidites | Unnatural Amino Acids | Linkers | Ligands

- Simplifying TIDES drug development by providing discovery, CMC development and the entire manufacturing supply chain under one roof
- Over 20 oligonucleotide production lines at all scales
- 100,000 L peptide solid phase total reactor volume
- **Novel technology platforms**: Biocatalysis, Thin Film Evaporation, TFF/precipitation, Continuous Purification

WuXi Biology



A comprehensive spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to hit finding, lead optimization, candidate selection, and beyond.

- **Comprehensive** discovery and translational biology centers, with **~3,000** experienced scientists and global footprints in 9 sites
- Early discovery screening platform, providing diverse hit finding solutions such as DEL/HTS/HTC/ASMS/FBDD*/Display and virtual screening, supported by informatics and data sciences
- **Thousands** of validated, 'ready to go', in vitro assays and in vivo models enabling discovery biology for comprehensive target classes, therapeutic areas and modalities
- **Extensive Oncology, Immunology, Infectious Disease, Inflammation, Neuroscience, Rare disease and Metabolic Disease indication**, offering an end-to-end service from discovery, through optimization and into clinical development
- **AAALAC** accredited and **BSL-2** certified on multiple sites
- Pathology and **CAP-certified** FACS capabilities supporting clinical biomarker services

Modalities

- Small molecules and peptides
- Oligonucleotides
- Bi-functional molecules, e.g. ADC/PDC/POC/TPD*
- Vaccines

Early Discovery

- New target discovery and mechanistic study
- Protein production & structural biology
- Screening & hit identification: DEL/HTS/HTC/ASMS/FBDD/Display/VS and libraries for small molecules, covalent, peptides, TPD* & macrocycles

Lead Optimization

- *In vitro* biochemistry and cell biology
- Cell panel screening
- MOA studies
- Radiometric assays
- Clinical biomarker development and validation

In Vivo Pharmacology

- Comprehensive *in vivo* disease model collection
- Targeted oncology and immuno-oncology
- Drug resistance and other novel models of higher translational value
- Tumor model database

*DEL: DNA Encoded Library; HTS: High Throughput Screening; HTC: High Content Screening; ASMS: Affinity Selection Mass Spectrometry; FBDD: Fragment-Based Drug Discovery; TPD: Targeted Protein Degradation

WuXi Testing - Drug R&D Testing



An integrated testing platform across the full life cycle of discovery and development to deliver innovative medicines to patients.

- Comprehensive *in vitro* and *in vivo* global DMPK services
- Preclinical services including GLP toxicology and safety pharmacology for successful Investigational New Drug (IND) / New Drug Application (NDA) filings
- GLP global bioanalytical services based on both LC-MS/MS and immunochemistry platforms

- WuXi IND (WIND): A full IND one-package submission that includes WuXi CMC, preclinical (disease specific pharmacology, DMPK, toxicology, and bioanalysis), clinical and regulatory affairs services.
- Long term toxicology, developmental DMPK and clinical bioanalysis in conjunction with clinical & CMC services that enable customers to move the molecules from IND to NDA.

Robust Data Privacy and Security Systems

Data security and privacy protection are among our highest priorities. Since our founding, WuXi AppTec has maintained a strong track record of data privacy based on rigorous security processes. Everything we discover, develop and deliver to our customers is secure, separated and protected.

Unwavering Commitment to Customers' IP Protection and the Highest Quality & Compliance Standards

802[1]

Quality Audits & Inspections by Global Customers and Regulatory Authorities in 2024

100%

Pass Rate with **0 Critical Findings**

58

Information Security Audits by Global Customers in 2024, with **0 Critical Findings**

24[2]

Main Operating Sites are **ISO/IEC 27001 Certified**

Notes: 1. Including 719 audits by customers and 69 inspections by regulatory authorities, and 14 audits by independent third parties.

2. Including all the main operating sites in China.

WuXi AppTec

Adhering to Global Regulatory Standards

- CMC platform (drug substance, drug product, analytical and regulatory CMC support) received FDA approval for New Chemical Entities
- CDMO approved by regulatory agencies in U.S., Canada, EU, Switzerland, China, Australia and New Zealand and Saudi Arabia, among others, to supply APIs, GMP intermediates and drug products for branded commercial drugs
- First CDMO to support the approval of an innovative drug in China through the Marketing Authorization Holder ("MAH") pilot program
- GLP toxicology laboratory certified by both OECD and NMPA, and passed FDA and NMPA inspections
- GLP/GCP bioanalytical laboratory passed FDA, OECD, NMPA and PMDA inspections

Fighting Diseases by Enabling High-Quality Medicines Faster

Advanced development of therapy approved by FDA and NMPA for the treatment of adult patients with **chronic hepatitis C virus genotypes 1 and 4 infections**

Advanced development of first oral-targeted therapy approved by FDA for the treatment of adult patients with **relapsed or refractory acute myeloid leukemia** with an isocitrate dehydrogenase-2 mutation

Supported the development of the first oral therapy approved by FDA and NMPA for the treatment of patients with **chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia**

Supported the acquisition of implied license of clinical trial from FDA for a small molecule drug for the treatment of **Alzheimer's Disease**

Provided all-round support for a BTK inhibitor to receive accelerated NDA approval for treatment of **mantle cell lymphoma** from FDA

Expedited an NDA submission to receive FDA approval for a breakthrough treatment of **ovarian cancer**

Trusted by around 6,000 Customers

WuXi AppTec

Our Continued Commitment to Sustainability

As a responsible corporate citizen, WuXi AppTec remains steadfast in its commitment to patients, customers, investors, employees, and communities to operate in a sustainable way both today and in the future.

- As a member of the United Nations Global Compact (UNGC), we committed to supporting its ten sustainability principles.
- As a Supplier Partner of the Pharmaceutical Supply Chain Initiative (PSCI), we committed to adhering to PSCI Principles.
- WuXi AppTec earns the Science Based Targets initiative (SBTi) validation for near-term emissions reduction targets.

Improved governance structure	Upholding Business Ethics Standards	Reduce environmental impact	Give back to local communities
Strategy Committee of the Board and Sustainability Committee oversee our sustainability strategies, policies, and performance. The Sustainability Office and Working Group execute the action plans.	Compliance with all applicable laws in operating jurisdictions and highest business ethics standards. In 2024, the Company's **24** sites achieved ISO 27001 certifications.	WuXi AppTec commits to reducing absolute Scope 1 and Scope 2 GHG emissions by **42%**, and absolute Scope 3 GHG emissions by **25%** by 2030, based on 2024 levels.	By following the Company's philanthropy and sponsorship policy and principles, we continuously manage our philanthropic actions strategically to actively serve the community.

Active Contributor to Our Global Communities








WuXi Global Forum

Explore advances in health and medicine

WuXi Innovation Day

Bring together leading voices from the regional and global communities

B.O.L.D series

Highlight bold think, bold action, and notable advances in tackling global health challenges

Public Welfare Events

Give back to local communities

Awards and Industry Recognition (Partially Listed)

Industry Leadership

TIME magazine's "World's Best Companies in Sustainable Growth 2025

Global Contract Research, Development and Manufacturing Organization Company of the Year (2022-2025)

Ranked among "The Future 50" (2020-2021)

Company of the Year (2018)

50 Smartest Companies (2019)

Heroes of Chemistry Award (2017)

Best Company in an Emerging Market (2014)

ESG Ratings

Received MSCI ESG "AAA" Leader Rating in 2025

First achieved a leadership level of "A" in 2024 CDP Water Security rating

Gold Medal awarded in EcoVadis sustainability rating (2024-2025)

Statistics as of Q3 2025 (September 30, 2025)